A Study of KD6005 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06213259
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05906524
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, China
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05723432
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Clinical Study of KD6001 in Advanced Solid Tumours
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Shanghai Kanda Biotechnology Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT05230290
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
© Copyright 2024. All Rights Reserved by MedPath